Following the positive outcome, Pfizer and Astellas will seek approval of Padcev-Keytruda in MIBC regardless of a patient’s ...

The combination of Keytruda and Padcev is taking another major step toward securing its position as a leading therapy in the ...

Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced positive topline results from the Phase ...

“PADCEV™ Plus Keytruda® Significantly Improves Survival for Patients with Muscle-Invasive Bladder Cancer Regardless of ...

BMO Capital Markets upgraded to Outperform from Market Perform and raised its price target to $130 from $82 on Thursday, ...

Merck says Keytruda plus Padcev improved survival and response rates versus chemotherapy in a Phase 3 muscle-invasive bladder ...

While acknowledging that Keytruda’s loss of exclusivity in 2028 represents the largest patent cliff in biopharma, BMO said it ...

Halozyme is seeing some progress in its global effort to defend intellectual property against alleged infringement by Merck & ...

ORR and 100% DCR observed with MICVO in combination with KEYTRUDA® (pembrolizumab) in 1L/2L+ R/M HNSCC at 3.6 mg/kg and 4.4 mg/kg Updated data from ongoing Phase 1 monotherapy study in 2L+ R/M HNSCC ...

The verdict is the latest twist in patent litigation between MSD and Halozyme, in which the latter is claiming that Keytruda ...

In a setback for Merck, a German court issued a preliminary injunction that prevents the company from distributing a new ...